$ALXN Headlines Tesla, Facebook, Netflix are Monday??s

New Post Public Reply Private Reply Replies (0) Message Board

Apr 9, 2014 at 7:07 PM

$ALXN Headlines

Tesla, Facebook, Netflix are Monday's stocks to watch 5:35 a.m. April 7, 2014 - Sue Chang
Facebook, Tesla slide into bear market territory 4:52 p.m. April 4, 2014 - Saumya Vaishampayan
Investors continue to pour out of biotech holdings 2:43 p.m. April 4, 2014 - Russ Britt
44 stocks on takeover target radar: Morgan Stanley 12:48 p.m. March 25, 2014 - blogs.marketwatch.com
U.S. stocks fall; Nasdaq skids 1.2% 4:40 p.m. March 24, 2014 - Anora Mahmudova
Apple gains on Comcast talk, new iPhone buzz 4:23 p.m. March 24, 2014 - Ben Eisen
First Solar, H-P, Symantec are stocks to watch 4:15 p.m. March 21, 2014 - Sue Chang
First Solar extends winning streak; Symantec plunges 3:06 p.m. March 21, 2014 - Ben Eisen
From every angle, technicals point to richer stocks 2:25 p.m. March 11, 2014 - The Trading Deck
U.S. stocks fall amid China worries 4:19 p.m. March 10, 2014 - Anora Mahmudova
Alexion rallies on upbeat outlook; Cliffs down on China 4:17 p.m. March 10, 2014 - Saumya Vaishampayan
Alexion bucks tide, gains on deal with France for blood disorder treatment 11:58 a.m. March 10, 2014 - blogs.marketwatch.com
Winning approval for new drugs may get harder, analyst warns 3:56 p.m. Feb. 28, 2014 - blogs.marketwatch.com
Yelp up on Yahoo deal; Apple gains as Icahn backs off 3:30 p.m. Feb. 10, 2014 - Saumya Vaishampayan
Corrective bounce, or viable market rally attempt? 11:34 a.m. Feb. 10, 2014 - Michael Ashbaugh
Utility stocks gain as Treasury yields lag 4:06 p.m. Feb. 4, 2014 - Wallace Witkowski
S&P 500 scores its best gain this year: stock market live blog recap 4:13 p.m. Jan. 30, 2014 - blogs.marketwatch.com
Facebook, Twitter highlight gainers; ADT unravels 3:55 p.m. Jan. 30, 2014 - Ben Eisen
Alexion shares leap on quarterly earnings, sunny forecast for 2014 10:56 a.m. Jan. 30, 2014 - blogs.marketwatch.com
Alexion Pharma shares surge 21%, S&P 500 best 9:43 a.m. Jan. 30, 2014 - Laura Mandaro

Nobody Expects a Spanish Disquistion 11:14 a.m. Today - Barrons.com
Alexion, Biogen Among Leading Big-Cap Biotechs 7:02 a.m. Today - Investors Business Daily
EPO Upholds Alnylam's McSwiggen Patent - Analyst Blog 7:00 p.m. April 8, 2014 - Zacks.com
Encouraging Pre-Clinical Data from Celldex - Analyst Blog 5:40 p.m. April 8, 2014 - Zacks.com
Intercept Pharma Prices 1M Share Offering, Shares Down - Analyst Blog 5:00 p.m. April 8, 2014 - Zacks.com
Pipeline Update from Idenix - Analyst Blog 4:55 p.m. April 8, 2014 - Zacks.com
A Sharp Pullback In Celldex Could Be A Window Of Opportunity 3:41 p.m. April 8, 2014 - Seeking Alpha
Halozyme Falls on Phase II Study Halt - Analyst Blog 12:10 p.m. April 8, 2014 - Zacks.com
Bristol-Myers Seeks FDA Approval for HCV Candidates - Analyst Blog 11:40 a.m. April 8, 2014 - Zacks.com
FDA Target Date for Gilead's HCV Candidate - Analyst Blog 11:30 a.m. April 8, 2014 - Zacks.com
RadNet Touches New 52-Week High - Analyst Blog 10:26 a.m. April 8, 2014 - Zacks.com
MannKind Slips on Afrezza Approval Delay - Analyst Blog 8:52 a.m. April 8, 2014 - Zacks.com
Idenix Pharmaceuticals (IDIX) Jumps: Stock Up 12.4% - Tale of the Tape 8:51 a.m. April 8, 2014 - Zacks.com
Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% - Tale of the Tape 8:45 a.m. April 8, 2014 - Zacks.com
Questcor Pharmaceuticals (QCOR) Shows Strength: Stock Surges 18.7% in Session - Tale of the Tape 8:44 a.m. April 8, 2014 - Zacks.com
Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Drugs Winner 5:00 p.m. April 7, 2014 - TheStreet.com
Momentum Slide to Continue for Netflix, Facebook? - Analyst Blog 1:21 p.m. April 7, 2014 - Zacks.com
FDA News Lifts Dyax Slightly - Analyst Blog 11:30 a.m. April 7, 2014 - Zacks.com
Exact Sciences Corporation (EXAS) in Focus: Stock Up 5.73% - Tale of the Tape 8:44 a.m. April 7, 2014 - Zacks.com
The Medicines Co's Fibrocaps Under U.S. Review - Analyst Blog 6:08 p.m. April 4, 2014 - Zacks.com

BioMed Realty Invests In Life Science Research Facilities Leased To Yale University, Yale-New Haven Hospital And Alexion Pharmaceuticals 7:00 a.m. April 7, 2014 - PR Newswire - PRF
Study Results, Stock Price Movements, Product Launches, and Updates on Court Case Trials - Analyst Notes on Medtronic, Alexion, DaVita, Thermo Fisher Scientific, and Medicines 8:00 a.m. April 4, 2014 - PR Newswire - PRF
Drug Approvals, Stock Price Movements, and New Tools for Standardization - Analyst Notes on Biogen Idec, Alexion, Actavis, Thermo Fisher Scientific, and Medtronic 8:00 a.m. March 26, 2014 - PR Newswire - PRF
Pre-market Biotech Picks -- Research on Merrimack Pharma, Alexion Pharma, Incyte, and Aastrom Biosciences 11:25 a.m. March 25, 2014 - PR Newswire - PRF
Conference Schedules, Upcoming Marathon Applications, Revised Guidance, and Acquisitions - Analyst Notes on Celgene, Medtronic, Alexion, Quest Diagnostics, and Illumina 8:00 a.m. March 14, 2014 - PR Newswire - PRF
Alexion Revises Upward 2014 Financial Guidance for Revenues and non-GAAP EPS 6:31 a.m. March 10, 2014 - BusinessWire - BZX
Collaborations, Conferences, and Recognitions - Analyst Notes on Illumina, Alexion, Medtronic, Sirona, and NPS Pharmaceuticals 2:08 p.m. March 5, 2014 - PR Newswire - PRF
Alexion to Present at the Barclays Global Healthcare Conference 11:00 a.m. March 5, 2014 - BusinessWire - BZX
Critical Alerts For Baidu.com, Gilead Sciences, Deere, Alexion Pharmaceuticals, and Ford Released By InvestorsObserver 10:31 a.m. March 5, 2014 - PR Newswire - PRF
NICE Confirms AGNSS Positive Assessment that Eculizumab (SolirisÂ&reg

is a Very Effective Treatment for aHUS Patients and Produces Substantial Quality-Adjusted Life Year Gains of a Magnitude Rarely Seen for a New Drug 8:02 p.m. March 3, 2014 - BusinessWire - BZX
Alexion Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2014 3:01 a.m. Feb. 28, 2014 - BusinessWire - BZX
Alexion to Present at the Cowen and Company 34th Annual Health Care Conference 11:01 a.m. Feb. 25, 2014 - BusinessWire - BZX
European Commission Grants Orphan Drug Designation to SolirisÂ® (Eculizumab) for Prevention of Delayed Graft Function (DGF) after Solid Organ Transplantation 7:30 a.m. Feb. 24, 2014 - BusinessWire - BZX
Critical Alerts For Twitter, Alexion Pharmaceuticals, Pfizer, Ctrip, and AngloGold Ashanti Released By InvestorsObserver 10:31 a.m. Jan. 31, 2014 - PR Newswire - PRF
Alexion Reports Fourth Quarter and Full Year 2013 Results and Provides Financial Guidance for 2014 7:31 a.m. Jan. 30, 2014 - BusinessWire - BZX
FDA Grants Orphan Drug Designation to SolirisÂ® (eculizumab) for Prevention of Delayed Graft Function (DGF) in Renal Transplant Patients 7:30 a.m. Jan. 21, 2014 - BusinessWire - BZX
Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2013 Results on Thursday, January 30, 2014 11:00 a.m. Jan. 16, 2014 - BusinessWire - BZX
Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeuticsâ?¢ for Rare Diseases 7:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Upcoming Presentations and Stock Price Movements - Research Report on Bard, Regeneron, Alexion, Seattle Genetics, and Isis Pharmaceuticals 9:00 a.m. Jan. 9, 2014 - PR Newswire
Alexion to Present at the JP Morgan 32nd Annual Healthcare Conference 11:00 a.m. Jan. 8, 2014 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kansai Medical Ushers in New Era of Cancer Research

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

VISTAR Oakland Workers Join Teamsters for Unity

Warehouse Workers Break Free from the Shackles Ever had that feeling, where enough is enough? That's where 37 warehouse workers at VISTAR find themselves, shaking off the dust and signing up with Teamsters Local 853. This ain't just a fleeting wind of change; it's the whole damn storm. Turning Points and Union Victories Think about it. This move by the VISTAR warehouse...

2GenPen & LordCap Team Up: Game-Changer in ABS?

New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...

Richard Huffman Joins IFA Board, Strengthens Franchise Ties

Ever wonder how the cogs in this massive machine called franchising keep turning? It's folks like Richard Huffman who step up to the plate, and his recent election to the International Franchise Association (IFA) Board of Directors is worth a second glance. Huffman: A Franchise Veteran Now, Huffman isn't some rookie in the world of franchising. You see, back in '94, he...

TomoIQ Unveils Money Finder at Money20/20 Event

Breaking Down Financial Barriers with AI In the hustle of Money20/20 USA in Las Vegas, TomoIQ dropped a financial bombshell with their latest tool, Money Finder. This isn't just another app in the sea of fintech solutions. Nope, this one promises to cut through the complexities that most folks face when trying to get their financial house in order. An AI Buddy for...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Revolutionizing Talent Matching with Match2's Latest Upgrades In the churn of today's recruiting jungle, candidates and employers have been grappling with disjointed systems and outdated approaches. Well, Match2 is cutting through that noise with some hefty upgrades. It's got some new toys in the shed—specifically, a beefed-up Universal Candidate Profile™ and an...

U.S. Millionaire Surge: Market Waves or Mirage?

Flashing Billions: Minting Millionaires at Breakneck Speed It sounds like something out of an 80s movie: every single day, over 1,200 folks in the United States become millionaires. Yep, you heard right. The UBS Global Wealth Report 2026 threw that number out, and it sure caught my attention. It's not everyday you hear about the U.S. cranking out millionaires like they're...

Noé Hinojosa Jr. Honored for Leadership in Business

From Bonds to Ballgames: Hinojosa's Impact Listen up, because this one’s more than just another accolade on a shelf. Noé Hinojosa Jr., a big gun over at TRB Securities, is getting the 2026 Hispanic Business Salute Award, and it's a doozy. Awarded by all the big wigs—UPS, NBC 5, Telemundo 39, and the Dallas Cowboys—this isn't a small pat on the back. It's a full-on...

Ama La Vida's New Coaching: More Than a Financial Plan

Breaking the Retirement Myth Retirement ain't just about sailing off into the sunset with a fat wallet. What happens when the honeymoon period of the "golden years" ends and you're left pacing the floorboards, unsure of what comes next? Enter Ama La Vida's fresh approach to retirement coaching, tackling the side of retirement that's rarely spoken about: identity,...